Merck sign on glass building facade blue sky

Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer

Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).

Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy.

sac-TMT is an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech.

Trial Efficacy And Safety Results

At final analysis, sac-TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.

Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.

However, sac-TMT did not meet its secondary endpoint of progression-free survival (PFS).

Although the therapy demonstrated a nominally improved benefit in objective response rate (ORR) favoring sac-TMT over TPC, investigators did not formally test this secondary endpoint under the prespecified analysis plan.

The therapy maintained a safety profile consistent with previously reported sac-TMT studies, revealing no new safety signals.

Expanding TroFuse Clinical Program

TroFuse-015 marks the second positive Phase 3 study from Merck’s global TroFuse clinical development program for sac-TMT.

The program currently comprises 18 ongoing global Phase 3 trials across multiple tumor types, representing the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date.

Merck is evaluating sac-TMT as both a monotherapy and in combination with immunotherapies spanning early-to-late-stage disease.

The studies cover endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers, with 14 of the 18 Phase 3 studies—including TroFuse-015.

MRK Price Action: Merck & Co shares were up 2.07% at $135.56 at the time of publication on Friday, according to Benzinga Pro data.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs
Share this article